Filing Details
- Accession Number:
- 0001209191-23-055843
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-17 17:52:08
- Reporting Period:
- 2023-11-15
- Accepted Time:
- 2023-11-17 17:52:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1856081 | Shafique Virani | C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2023-11-15 | 18,000 | $2.22 | 158,351 | No | 4 | M | Direct | |
Class A Common Stock | Disposition | 2023-11-15 | 18,000 | $6.51 | 140,351 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2023-11-15 | 3,603 | $7.18 | 136,748 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2023-11-15 | 18,000 | $0.00 | 18,000 | $2.22 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
397,469 | 2030-03-03 | No | 4 | M | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (Right to Buy) | $8.55 | 2033-02-01 | 0 | 212,507 | Direct | |
Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2032-02-04 | 0 | 80,450 | Direct | |
Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2022-02-04 | 2032-02-04 | 0 | 5,436 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2033-02-01 | 0 | 212,507 | Direct |
2032-02-04 | 0 | 80,450 | Direct |
2032-02-04 | 0 | 5,436 | Direct |
Footnotes
- Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
- Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.